Use this Interactive Decision Support Tool to compare your choice of therapy for patients with β-thalassemia with those of 4 renowned thalassemia experts.
Provide optimal care for patients with β-thalassemia, considering the available clinical evidence as well as expert and guideline recommendations
Plan therapeutic approaches to reducing transfusion dependence through use of erythroid maturation agent
Evaluate emerging gene therapy strategies and their potential role in management of patients with β-thalassemia
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of Hematology
Aflac Cancer & Blood Disorders Center
Children's Healthcare of Atlanta
Pediatric Hematologist Oncologist
Director, Thalassemia Program
Department of Pediatric Hematology/Oncology
Professor of Pediatrics
Perelman School of Medicine of the University of Pennsylvania
Director, Thalassemia Program
Children's Hospital of Philadelphia
Department of Pediatrics
Weill Cornell Medicine
New York, New York
Senior Director, Educational Strategy
Associate Director, Scientific Services
Director, CME Program Development
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for physicians and other healthcare providers who care for patients with β-thalassemia.
The goal of this activity is to improve the competence of learners to apply the latest practice-changing data in the individualized clinical management of patients with β-thalassemia.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2021, through April 21, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.
You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.
This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for monitoring or treating individuals with β-thalassemia. The information provided is based on clinical guidelines for the management of patients with β-thalassemia and expert recommendations of Jeanne Boudreaux, MD; Stephanie A. Fritch Lilla, MD; Janet L. Kwiatkowski, MD, MSCE; and Sujit Sheth, MD.
The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Although the information contained in the “Interactive Decision Support Tool: Expert Management Recommendations for Patients With β-Thalassemia” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.
Any trademarks are the property of respective companies.
© 2021 Clinical Care Options, LLC. All rights reserved.
Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)
On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)
Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD: top picks of nonmalignant hematology studies from ASH 2020 as reported by CCO
From Clinical Care Options (CCO), expert answers to audience questions from 2 live meetings on contemporary management of hemophilia A